AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05218356 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Electrocardiogram
Description: valuation by the principal investigator or assistant physician with a complete physical examination
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NEWS-2 score
Description: assessment of the participant by the NEWS-2 score.
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NEWS-2 score
Description: assessment of the participant by the NEWS-2 score.
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WHO score
Description: assessment of the participant by the score of the World Health Organization.
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: WHO score
Description: assessment of the participant by the score of the World Health Organization.
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical examination
Description: evaluation by the principal investigator or assistant physician
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical examination
Description: evaluation by the principal investigator or assistant physician
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVID-19-Related Symptoms assessment
Description: will be completed by the study staff member based on patient status and answers.
Study NCT05218356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: COVID-19-Related Symptoms assessment
Description: will be completed by the study staff member based on patient status and answers.
Study NCT05451784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD1+ TILs (NUMARZU-001) product infusion
Description: The cryopreserved NUMARZU-001 product will be thawed in a 37ºC water bath and will be infused by gravity, a 5 mL to 10 mL/ minute.~Concomitant medications will be given to the patient starting within 24 hours before NUMARZU-001 product infusion. This therapy will include the following:~* Hydration as per institutional standards (Saline solution 0,9% NaCl 500ml every 8 hours) 24 hours before the NUMARZU-001 product infusion.~* Within 30 to 60 minutes before infusion of NUMARZU-001, premedicate the patient with paracetamol (1 g) and dexclorfeniramina (5 mg IV), or another H1- histamine antagonist.~Continuous supervision of the patient by site medical staff is required until completion of infusionof the NUMARZU-001 product, to monitor for potential signs and symptoms (e.g. hypersensitivityreaction).
Study NCT05462132 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYNB1353
Description: SYNB1353 IMP is formulated as a nonsterile solution intended for oral administration. SYNB1353 is subsequently lyophilized to form the bulk drug product. The lyophilized product is sieved into powder form and filled into high-density polyethylene (HDPE) bottles. Placebo will be manufactured using an inactive powder that is color matched to the SYNB1353 drug product. L-Methionine will be supplied as dry powder and will be suspended in a diluent prior to use.
Study NCT05094765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMT
Description: Fecal Microbiota Transplantation
Study NCT04071548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIIT Exercise
Description: HIIT exercise bike protocol~* 3 minute warm up~* Intervals of 10x 60 sec of 80-95% of heart rate reserve Heart rate reserve = Max Heart rate - Resting Heart rate § Max heart rate = 220-age~* 10x60 second Recovery period~* 5 minute cool-down
Study NCT05514587 — intervention group
Intervention type: BEHAVIORAL
Intervention: Meaning of Life Questionnaire (MLQ)
Description: Completion of questionnaires at crisis centre entry and 3 months later.
Study NCT04871061 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PENG Block
Description: Pericapsular Nerve Group Block
Study NCT04871061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional opioid analgesia (Fentanyl)
Description: standardised intravenous opioid
Study NCT04743583 — intervention group
Intervention type: DEVICE
Intervention: Endosonography B-mode examination
Description: Endobronchial ultrasound (EBUS) or Endoscopic with bronchoscope (EUS-B) B-mode examination and sampling, when indicated, of lymphadenopathy
Study NCT05269706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 200mg
Description: Cannabidiol 200mg (twice daily)
Study NCT05269706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex 400mg (twice daily)
Study NCT05269706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol 400mg
Description: Cannabidiol 400mg (twice daily)
Study NCT05269706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching Placebo (Twice Daily)
Study NCT04990323 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Description: Single UM171-Expanded CB transplant (CD34+: 2.5-50x10\^5/kg, CD3+>1x10\^6/kg)
Study NCT05123664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Capsule
Description: 1 cap daily at same time of the day with or without food for 4 weeks
Study NCT05123664 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Capsule
Description: 1 cap daily at same time of the day with or without food for 4 weeks
Study NCT05923242 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Intervention Authoring Software (CIAS)
Description: CIAS is a web based intervention. The CIAS tool walks the participant through a Motivational Interviewing process whereby they think through the reasons for and against completing screening. CIAS makes use of an automated avatar (Emmi) who is programed to ask them questions and lead them through several topic areas related to screening. The CIAS pathways include options for participants to request a link of resources after they complete each session and for patients to request a list of the cancer treatments listed in their study records in order to confirm their understanding of their cancer history.
Study NCT05853549 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical surface monitoring system
Description: An optical surface monitoring system (OSMS) could achieve continuous monitoring of patient position through a nonradiographic and noninvasive technology, which has been widely applied to many sites of radiation therapy, including breast, intracranial, head and neck, abdomen, and extremities
Study NCT06364501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KH801
Description: KH801 is an injection solution
Study NCT05315700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-114
Description: ORIC-114 oral daily
Study NCT05315700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: 21 days for up to 4 cycles
Study NCT05091736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, blood glucose monitor for personal use
Description: measurement of the blood glucose concentration using the blood glucose monitor for personal use (BG-709b)
Study NCT05091736 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: blood glucose measurement, laboratory reference device
Description: measurement of the blood glucose concentration using a laboratory reference device
Study NCT05469269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Education
Description: Education: QR codes will be posted at each barber's station within a barber shop, as well as on other study materials located within the shop. The QR code recruitment mechanism will encourage potential participants to complete a Prostate Cancer Knowledge and Risk Assessment questionnaire (ie. Screener) which acts as a screener for study eligibility. The screener can be completed by scanning the QR code with a cell phone while in the barbershop. Barbers will encourage their clients to complete the Screener.
Study NCT05469269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education by Community Navigator
Description: A community navigator will be onsite to assist in information delivery, navigation to resources, and encourage the completion of the Screener through the QR code. Participants can opt to connect with the community navigator if they have questions, need assistance in scheduling a PSA screening, or if they have other resource needs. The community navigator will help participants connect with a primary care provider to continue with all preventive healthcare recommendations.
Study NCT05469269 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education at Community Outreach Screening Event
Description: The Community Navigator will set up PSA screening events at specific barber shops for participants who wish to move forward with screenings.
Study NCT05245916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397
Description: IBI397 single-agent dose escalation： Subjects will receive IBI397 until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Study NCT05245916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397+Sintilimab
Description: IBI397 in combination with sintilimab： Subjects will receive IBI397 combination therapy with sintilimab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Study NCT05245916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI397+Rituximab
Description: IBI397 in combination with rituximab： Subjects will receive IBI397 combination therapy with rituximab until disease progression, unacceptable toxicity, withdrawal of consent, occurrence of other conditions that require discontinuation of study treatment, or the treatment duration has reached 24 months, whichever occurs first
Study NCT05845905 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic conditioning
Description: Remote ischemic conditioning (RIC) is induced by 4 cycles of 5 min of upper limb ischemia followed by 5 min reperfusion. Limb ischemia was induced by the inflation of an automated cuff to the pressure rising by 20 mmHg from baseline systolic pressure. RIC will be conducted twice daily for 7 days.
Study NCT05845905 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: Sham-RIC is performed in the same way as the treatment group except that the blood pressure cuff is inflated to 60 mmHg, which produces mild pressure sensations but has no blocking impact on blood flow.
Study NCT06463392 — intervention group
Intervention type: OTHER
Intervention: No Intervention: Observational Cohort
Description: No intervention is scheduled for this observational study.
Study NCT04530058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 500 mg twice a day, administered orally or via gastric tube.
Study NCT04530058 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo twice a day, administered orally or via gastric tube.
Study NCT05768763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community-enhanced reach activities
Description: We will conduct a series of community engagement activities designed to reach persons at risk for HIV, undiagnosed with HIV or diagnosed, or hypertension, and fallen out of care, working closely with community health workers, integrated in the community health system.
Study NCT05768763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Person-centered care delivery
Description: Structured approach to provide patient-centered biomedical options for HIV prevention (dynamic choice prevention). Tailored services for HIV treatment support using structured life stage evaluation and assessment plan (LEAP) for youth, pregnant women, and persons with or at risk of HIV viral non-suppression, that includes counselling for heavy alcohol users. Structured approach to offer telehealth for severe hypertension follow up.
Study NCT05768763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data system enhancement to improve reach and person-centered delivery
Description: Both community-enhanced reach and person-centered delivery will be strengthened through a customized in-country Ministry of Health-compatible community health worker smartphone app and two-way data system linking community health workers and clinical records.
Study NCT05768763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care in Uganda and Kenya
Study NCT05454969 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: One-4-ALL Initiative
Description: We can successfully implement a patient app that will be used by families to 1) increase throughput for all patients, including minoritized, low-income, and low health literacy patients, and 2) reduce administrative burdens on providers.
Study NCT05454969 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Patients will receive standard of care.
Study NCT06499233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trimethoprim/Sulfamethoxazole
Description: Patients received Trimethoprim/Sulfamethoxazole (TMP/SMX) 480 mg p.o. every day as PJP Prophylaxis; Treatment duration: at least 28 days, adjusted by the clinician based on the severity of the patient's condition, the patient's tolerance to the drug and treatment willingness).
Study NCT06138743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARO-DM1 for Injection
Description: single or multiple doses of ARO-DM1 by intravenous (IV) infusion
Study NCT06138743 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calculated volume to match active treatment by IV infusion
Study NCT05785585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylcobalamin
Description: Treatment with Methylcobalamin during 12 weeks
Study NCT05785585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cyanocobalamin group
Description: Treatment with Cyanocobalamin during 12 weeks
Study NCT05785585 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Treatment with microcrystalline cellulose during 12 weeks
Study NCT06375746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized video
Description: After enrollment and assignment to the intervention group, patients will receive a link to a personalized video describing the different induction methods by a text message.
Study NCT05784324 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT06410001 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural Spinal Cord Stimulation (eSCS)
Description: The spinal cord stimulator system (Abbott Eterna system implantable pulse generator (IPG), charger, and TriCentrus lead) will be used for this study which is manufactured by Abbott Laboratories. The The stimulators will be surgically inserted above the dura in the spinal canal and administer an electrical signal from the neurostimulator to specific sections of the spinal cord underlying the electrodes. The duration of implantation will be 10 years (the longevity of the device battery). The device will not be removed unless it causes complications such as malfunction, illness, or other harm.~The device can also be removed electively for any reason.
Study NCT05500274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Testimonial videos will be played including those that describe the testing experience and their motivations for testing. This approach combines self-affirmation with misinformation correction to take advantage of the ability to promote adaptive COVID-19 prevention behaviors. The self-affirmation activity will always precede the presentation of the testimonial videos as leading with misinformation correction can be construed by some as a threat to one's self-adequacy.
Study NCT05500274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Motivational
Description: This is a Type I network intervention that includes specific training on mobilization of network members. Training occurs in a group-based setting of 8-10 enrolled participants facilitated by a community facilitator and Motivational Interviewing trained interventionist. At 30 days, a 15-20-minute phone booster communication session reinforces the intervention content
Study NCT06561360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib orally twice daily (b.i.d.) continuously in cycles of 4 weeks (28 days) for a total of 4 cycles.
Study NCT06561360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab will be administered concomitantly with vemurafenib starting at cycle 2 of treatment in cycles of 4 weeks.
Study NCT06561360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cladribine
Description: Cladribine IV on days 1-5 concurrently with rituximab.
Study NCT06561360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab on days 1-5 concurrently with rituximab.
Study NCT04948541 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: osa treatment
Description: different treatments can be included
Study NCT04948541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no treatment
Description: no treatment was undergone
Study NCT05888389 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cranial Nerve Block Anesthesia Combined With Sedative Anesthesia
Description: Patients in the nerve block anesthesia combined with sedative anesthesia group will first receive cranial nerve blocks under standard monitoring. At the same time, intravenous dexmedetomidine infusion is started for sedation at a rate of 2-4ug/kg for 10 minutes, followed by a continuous infusion of 0.5-1ug/kg/h until the Richmond Agitation-Sedation Scale (RASS) of -3.
Study NCT05888389 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia
Description: Patients will be induced with propofol or etomidate, sufentanil , rocuronium or cisatracurium .
Study NCT05813626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab (240 mg Q3W for 3 cycles) combine with chemotherapy
Study NCT06004284 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa
Study NCT06004284 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise group
Description: The exercise training program will be applied for 8 weeks, 3 days a week and for an average of 20-30 minutes. After the maneuver is taught, stretching exercises lasting 5 minutes for warm-up purposes and posture and core exercises lasting 25 minutes will be taught. Among the stretching exercises, quadratus lumborum stretching, hamstring stretching, erector spina stretching, hip extensor stretching exercises will be applied. Posterior pelvic tilt exercise will be performed as a control and smoothing exercise for the vertebrae of the lumbar and pelvic region. Among the core stabilization exercises, bridging, plank, plank in side lying, abdominal strengthening, cross arm leg lifting exercises in crawling position will be performed. Each exercise position will be required to be maintained for 8 seconds and to do 10-15 repetitions.
Study NCT04887090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture and Drug Compound Technology
Description: Before operation: The points of the meridian: Hegu, Neiguan, Chize, Zusanli, both sides are taken. TEAS (transcutaneous electrical acupoints stimulation) was performed every day for three days before the operation, using the Han's acupoint nerve stimulator to adjust the density and density waveforms at a frequency of 2/100 Hz (Hz). Current intensity is 10mA, and all acupuncture points are continuously stimulated for 30 minutes. During the operation: take the acupoints Hegu, Neiguan, Houxi, and Zhigou on both sides and give TEAS 30 minutes before induction of anesthesia. The stimulation intensity and frequency are the same as those before the operation until the end of the operation. Postoperative: Take the acupoints Chize, Waiguan, Taichong, and Yanglingquan, and take both sides. TEAS will be performed every 12 hours from the first day after surgery. Each treatment is 30 minutes until 48 hours after surgery. The intensity and frequency are the same as before surgery.
Study NCT04887090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine perioperative management
Description: Comprehensive evaluation of cardiopulmonary function, preparation of respiratory tract, active treatment of coexisting diseases before operation, correction of water and electrolyte disorders and hypoproteinemia before operation. To prevent cross-infection during the operation, the intraoperative blood volume should be supplemented within the tolerance of cardiac function, the tissue perfusion should be sufficient, and the infusion should be uniform. Strengthen respiratory care after operation, prevent cardiovascular complications, pay attention to the speed and amount of blood transfusion, encourage early activities, promote lung expansion and prevent thrombophlebitis.